Clinical trials: Phase 4, active
Peripheral Arterial Disease
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities.
- Trial name
- NCT02842424
- Testing
- Ramipril
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Nebraska
Severe Hemophilia A, Moderate Hemophilia A
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and <70 years…
- Trial name
- Beyond ABR (NCT05181618)
- Testing
- Emicizumab
- Where
- 26 sites in United States, Brazil and 10 more
- Volunteers
- 136 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Edema, Congestive Heart Failure
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
DECONGEST-AHF compares three initial treatments for adults admitted with suspected pulmonary congestion due to acute heart failure: intravenous furosemide, intravenous isosorbide dinitrate, or both medicines together.
- Conditions
- Pulmonary Edema, Congestive Heart Failure, Acute Heart Failure
- Trial name
- DECONGEST-AHF (NCT05276219)
- Testing
- Furosemide Injection, Isosorbide Dinitrate, Furosemide and isosorbide dinitrate
- Where
- 5 sites in Denmark
- Volunteers
- 1,041 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's…
- Trial name
- NCT06045754
- Testing
- Vedolizumab, Adalimumab, Ustekinumab
- Where
- 48 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Takeda
Pouchitis
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Although many people will develop recurrent pouchitis (inflammation of the ileal pouch-anal anastomosis or J-pouch after colectomy for ulcerative colitis) after an initial episode of pouchitis, there are currently no effective…
- Trial name
- NCT06312683
- Testing
- Rifaximin 550 MG Oral Tablet [XIFAXAN]
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of North Carolina, Chapel Hill
Hypertensive Disorders of Pregnancy, Preeclampsia
AtorvaStatin Postpartum and Reduction of Cardiovascular risK
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum.
- Conditions
- Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
- Trial name
- SPARK (NCT06632379)
- Testing
- Atorvastatin 10 mg
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Ohio State University
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization.
- Trial name
- V-INTERVENTION (NCT06909565)
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 147 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Duke University
Chronic Graft Versus Host Disease
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older.
- Trial name
- NCT07135973
- Testing
- Belumosudil
- Volunteers
- 26 people
- Sponsor
- Sanofi
Vasodilatory Shock
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock.
- Trial name
- NCT07212686
- Testing
- Angiotensin-II
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Mild Autonomous Cortisol Secretion (MACS)
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as…
- Trial name
- NCT07247058
- Testing
- Osilodrostat (Isturisa)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Asthma
Ventilation and Perfusion in Asthmatics
Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation…
- Trial name
- NCT07426458
- Testing
- Albuterol Sulfate, Albuterol-Budesonide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Laparoscopic Surgery, Visceral Pain, Postoperative
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Visceral pain following laparoscopic surgery is frequently underestimated, yet it is associated with a range of adverse outcomes.
- Conditions
- Laparoscopic Surgery, Visceral Pain, Postoperative, Anrikefon, Patient-controlled Intravenous Analgesia
- Trial name
- NCT07525986
- Testing
- High-dose anrikefon, Medium-dose anrikefon, Low-dose anrikefon
- Where
- 4 sites in China
- Volunteers
- 140 people
- Sponsor
- Peking University First Hospital
Diabetic Retinal Disease
Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents
A considerable hurdle to the development of novel, more effective therapies for diabetic retinal disease is the limited number of primary endpoints available for use in regulatory trials.
- Trial name
- AS (NCT07567833)
- Testing
- Anti-Vascular Endothelial Growth Factor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jaeb Center for Health Research
Any Patient Under General Anesthesia With Propofol Induction
A Novel Two-Step Dosing Induction Strategy (The Propofol Challenge Test) to Minimize Propofol Injection Pain
Propofol is the most widely used intravenous hypnotic agent for the induction of general anesthesia owing to its rapid onset and short duration of action.
- Trial name
- PROTECT (NCT07763548)
- Testing
- Bolus injection, Fractionned onjection
- Where
- Belgium
- Volunteers
- 2,000 people
- Sponsor
- Erasme University Hospital
Crohn Disease, Perianal Fistula
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Crohn's disease is an inflammatory bowel disease characterized by relapses and remissions, causing lesions throughout the digestive tract and accompanied by diarrhea, abdominal pain, and nutritional disorders.
- Conditions
- Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
- Trial name
- RIS-PERIANAL (NCT07872449)
- Testing
- Risankizumab
- Where
- 4 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Yuki Horio
MAFLD in Prediabetes and Diabetes
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus.
- Trial name
- SGLT2 (NCT07891234)
- Testing
- Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Sherihan AboElyazed Mohamed Khalil
Macular Degeneration, Diabetic Retinopathy
Iopidine to Decrease Intraocular Pressure Rise After Injections
This is a prospective, randomized, controlled, open-label, single-site investigator-initiated clinical trial. A total of 120 participants will be randomized in a 1:1 ratio either to receive one drop of apraclonidine 1% ophthalmic…
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07891910
- Testing
- Apraclonidine 1.0% ophthalmic solution
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Retina Consultants of Delmarva
Melasma (Facial Melasma)
Efficacy and Safety of Triple-Combination Cream Plus Microneedling Along With Tranexamic Acid Versus Platelet-Rich Plasma in the Treatment of Moderate-to-Severe Melasma: A Randomized Comparative Study
Background Melasma is a chronic acquired pigmentary disorder characterized by symmetrical hyperpigmented macules and patches, predominantly affecting the face.
- Trial name
- NCT07893067
- Testing
- Group B (Triple Combination Cream + Microneedling + Platelet-Rich Plasma)
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Bangladesh Medical University
Melanoma, Non Small Cell Lung Cancer
Dabrafenib and/or Trametinib Rollover Study
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
- Trial name
- NCT03340506
- Testing
- dabrafenib, trametinib
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Hepatitis C, Chronic
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Background: Chronic hepatitis C infects the liver. It may scar the liver. This is called cirrhosis and may lead to liver cancer or death. Current chronic hepatitis C treatments cure most people.
- Conditions
- Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
- Trial name
- NCT03520660
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)